Drug intelligence / Profile preview

FBX-102

Development stage: Unknown
Lead developer: Forte Biosciences
Modality: Gene Therapies

Overview

FBX-102 is an early-stage gene therapy candidate developed by Forge Biologics. It was initially identified in the company's internal pipeline at the proof-of-concept stage, though its specific therapeutic target and primary indication were never publicly disclosed. Given Forge Biologics' specialization as a contract development and manufacturing organization (CDMO) for adeno-associated virus (AAV) products, FBX-102 is presumed to be an AAV-based gene therapy. The program is no longer listed on the company's active pipeline, indicating it has likely been discontinued or deprioritized.

Targets

GALC (Galactosylceramidase)

Beyond the preview

Go deeper on FBX-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FBX-102.

Explore the full profile